These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34446063)

  • 21. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
    Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
    Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping.
    Du Z; Lu T; Gao M; Tian L
    Acta Diabetol; 2022 Dec; 59(12):1539-1549. PubMed ID: 36002590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
    Lyu X; Zhu X; Zhao B; Du L; Chen D; Wang C; Liu G; Ran X
    Sci Rep; 2017 Mar; 7():44865. PubMed ID: 28322294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
    Emral R; Haymana C; Demirci I; Tasci I; Sahin M; Cakal E; Ata N; Unluturk U; Demir T; Ertugrul D; Sahin I; Atmaca A; Celik O; Caglayan M; Arga KY; Dagdelen S; Salman S; Satman I; Sonmez A
    Diabetes Ther; 2021 Nov; 12(11):2857-2870. PubMed ID: 34398433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
    Kim YG; Byun J; Yoon D; Jeon JY; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    J Diabetes Res; 2016; 2016():1423191. PubMed ID: 28119930
    [No Abstract]   [Full Text] [Related]  

  • 31. The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials.
    Paschou SA; Siasos G; Bletsa E; Stampouloglou PK; Oikonomou E; Antonopoulos AS; Batzias K; Tsigkou V; Mourouzis K; Vryonidou A; Tentolouris N; Vavouranakis M; Tousoulis D
    Curr Pharm Des; 2020; 26(46):5980-5987. PubMed ID: 32303166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
    Morieri ML; Bonora BM; Longato E; Di Camilo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2020 Oct; 22(10):1925-1934. PubMed ID: 32691492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
    Savarese G; Perrone-Filardi P; D'Amore C; Vitale C; Trimarco B; Pani L; Rosano GM
    Int J Cardiol; 2015 Feb; 181():239-44. PubMed ID: 25528528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
    Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
    J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
    Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
    J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure　- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Sato K; Sai S; Sugano A; Obara K; Aonuma K
    Circ J; 2017 Oct; 81(11):1662-1669. PubMed ID: 28592726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
    Nishimura R; Kato H; Kisanuki K; Oh A; Hiroi S; Onishi Y; Guelfucci F; Shimasaki Y
    BMJ Open; 2019 Mar; 9(3):e025806. PubMed ID: 30826768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.